Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. rapidex

RapidEx SIGNED

Validation of a point-of-care H-FABP test for a rapid exclusion of Acute Myocardial Infarction in patients with cardiac complaints.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 RapidEx project word cloud

Explore the words cloud of the RapidEx project. It provides you a very rough idea of what is the project "RapidEx" about.

diagnosis    ce    plan    hcps    plasma    suspected    occurrence    netherlandsbelgium    thereby    fabp    5    biomarker    innovative    device    addressable    confidence    alone    validate    guidelines    admissions    least    professionals    medico    phased    trials    leads    maastricht    price    insurers    1    chest    gross    form    margin    blood    marked    hcp    aids    intended    80    care    mln    basis    core    consult    primary    protein    technologies    rule    binding    medical    proportion    drop    select    improvement    physician    true    sustainable    pressing    nw    acid    outcomes    sme    2008    2018    consequently    fatty    pain    emergency    amounts    reimbursement    preparation    referrals    ultra    unnecessary    complaints    advantages    ruling    market    introduction    myocardial    health    acute    healthcare    performing    spun    adoption    request    offers    patients    diluted    proprietary    ami    inspection    tests    point    infarction    heart    economically    majority    there    diagnosed    sent    population    helps    home    company    hospital    revenue    saving    uk    university    18    reduce    clinical    fabpulous    trt    decrease    rapid   

Project "RapidEx" data sheet

The following table provides information about the project.

Coordinator		 FABPULOUS BV 

Organization address
address: OXFORDLAAN 55
city: MAASTRICHT
postcode: 6229 EV
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Project website http://fabpulous.com/
 Total cost 1˙633˙750 €
 EC max contribution 1˙633˙750 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2017-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FABPULOUS BV NL (MAASTRICHT) coordinator 1˙633˙750.00

Map

 Project objective

There is a pressing need for improvement of the diagnosis of acute myocardial infarction (AMI) for healthcare professionals (HCP). 1–1,5% of the population consult a physician each year with chest pain complaints. While the majority (60–80%) of these patients are sent to a hospital for further inspection, eventually AMI is diagnosed in only 8–18% of these cases. Consequently, a rapid, objective test that helps to better select patients suspected of AMI by HCPs would reduce the number of unnecessary hospital referrals and admissions, thereby saving costs and contributing to a more sustainable healthcare.

FABPulous (SME) is a medical device company spun out of Maastricht University in 2008. The core of the company is its innovative proprietary technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages over current technologies in point-of-care and home testing.

The CE-marked H-FABP True Rapid Test (H-FABP TRT) developed by FABPulous aids the HCP in ruling out AMI with a very high level of confidence. It is based on the heart-type fatty acid binding protein (H-FABP), which can be used as biomarker for AMI. With H-FABP TRT a physician is able to rule out the occurrence of an AMI for a large proportion of patients suspected of AMI. It is intended for use in both primary and emergency care.

In this project FABPulous seeks to medico-economically validate H-FABP TRT in primary (NetherlandsBelgium) and emergency care (UK) by performing two clinical trials. Outcomes of these studies lead to adoption of H-FABP TRT in medical guidelines and form the basis of a request for reimbursement towards health insurers. In this project FABPulous will improve the production process as well in order to decrease the cost price to €5 per test.

The addressable market in NW Europe alone amounts to at least 2 mln tests. The phased introduction plan leads to €8.6 mln revenue with a gross margin of €6.5 mln in 2018.

 Deliverables

List of deliverables.
Clinical study protocol emergency care trial Documents, reports 2019-04-15 17:08:30

Take a look to the deliverables list in detail:  detailed list of RapidEx deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RAPIDEX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RAPIDEX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More